Denali Therapeutics DNLI 深 滬
等待開盤 09-17 09:30:00 美东时间
20.06
-0.320
-1.57%
華盛通- 最 高20.51
- 今 開20.40
- 成交量 185.56万股
- 最 低 19.87
- 昨 收 20.38
- 總市值 32.07亿
- 52周最高 27.30
- 市盈率 靜 --
- 換手率 1.16%
- 52周最低 13.75
- 委 比 33.66%
- 總股本 1.60亿
- 歷史最高 93.94
- 量 比 1.29
- 振 幅 3.14%
- 歷史最低 10.57
- 每 手 1
- 風險率 3.23%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 瑞杰金融维持英伟达"强力买入"评级，目标价从330美元升至352美元；瑞穗下调美光科技目标价从1375美元降至1300美元
今日重点评级关注：摩根大通：维持Ultragenyx Pharmaceutical"超配"评级，目标价从75美元升至80美元；瑞杰金融：维持英伟达"强力买入"评级，目标价从330美元升至352美元
08-26 08:37
B. Riley Securities Maintains Buy on Denali Therapeutics, Raises Price Target to $35
B. Riley Securities analyst Mayank Mamtani maintains Denali Therapeutics (NASDAQ:DNLI) with a Buy and raises the price target from $30 to $35.
08-26 01:47
Aura Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Aura Biosciences reported Q2 2026 financial results and business updates, highlighting the full enrollment of its Phase 3 CoMpass trial for bel-sar in early choroidal melanoma, exceeding targets and on track for 2H 2027 topline data. The company refocused its strategic plan on ocular oncology, deprioritizing the NMIBC program while maintaining data collection. Organizational restructuring and leadership appointments were announced to align resour...
08-11 11:00
美股大行评级 | 花旗下调美光科技目标价从1400美元降至1150美元；爱彼迎、Datadog、Cloudflare、Etsy、Natera、拉夫劳伦获多家大行上调目标价
今日重点评级关注：康托·菲茨杰拉德：维持InflaRx"超配"评级，目标价从4美元升至6美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从19美元升至20美元
08-10 19:24
UBS Maintains Buy on Denali Therapeutics, Raises Price Target to $34
UBS analyst Michael Yee maintains Denali Therapeutics (NASDAQ:DNLI) with a Buy and raises the price target from $25 to $34.
08-08 07:37
财报速睇 | Denali Therapeutics 2026财年Q2营收0.04亿美元，同比增长；归母净利润亏损1.28亿美元，同比亏损扩大2.8%
华盛资讯8月7日讯，Denali Therapeutics公布2026财年Q2业绩，公司Q2营收0.04亿美元，同比增长，归母净利润亏损1.28亿美元，同比亏损扩大2.8%。
08-07 12:05
财报速睇 | Denali Therapeutics 2026财年Q2营收0.04亿美元；归母净利润亏损1.28亿美元，同比亏损扩大2.8%
华盛资讯8月7日讯，Denali Therapeutics公布2026财年Q2业绩，公司Q2营收0.04亿美元，归母净利润亏损1.28亿美元，同比亏损扩大2.8%。
08-07 08:12
Denali Therapeutics Q2 EPS $(0.68) Misses $(0.65) Estimate, Sales $3.604M Miss $14.613M Estimate
Denali Therapeutics (NASDAQ:DNLI) reported quarterly losses of $(0.68) per share which missed the analyst consensus estimate of $(0.65) by 4.62 percent. This is a 5.56 percent increase over losses of $(0.72) per share from the same period last year. The company reported quarterly sales of $3.604 mil...
08-07 04:04
美股大行评级 | 谷歌绩后分歧大！4家大行上调、10家下调目标价；特斯拉遭8家大行下调目标价；ServiceNow、德州仪器、西屋制动、AT&T、CSX等获多家大行上调目标价
今日重点评级关注：伯恩斯坦：维持ServiceNow"跑赢大市"评级，目标价从236美元升至248美元；HC Wainwright & Co.：维持NovoCure"买入"评级，目标价从46美元升至52美元
07-24 11:37
Morgan Stanley Maintains Overweight on Denali Therapeutics, Raises Price Target to $36
Morgan Stanley analyst Matthew Harrison maintains Denali Therapeutics (NASDAQ:DNLI) with a Overweight and raises the price target from $35 to $36.
07-24 02:04
